The seventh bid "Chengdu made" innovative medicine for the seventh bid "Chengdu made" on the list

On July 12, under the guidance of relevant departments such as the National Medical Insurance Bureau, the seventh batch of centralized procurement of drugs for drugs for drugs was opened in Nanjing. Although the official announcement has not yet officially announced the results, many listed companies have issued a bid to win the bid. Among them, 15 varieties of Chengdu enterprises in Kellen Pharmaceutical and Yuandong Biological are on the list.

The average price reduction of 60 drugs is 48%

The centralized procurement of drugs in the country is popular in general to organize large -scale drugs to "group purchase" in various provinces and regions of the country to reduce the price of drugs through the method of "replacement of price".

Since its launch in November 2018, the National Organization Pharmaceutical Collection has completed six batches of 234 drugs, with an average of 53%of the drug prices, which involved 30%of the total annual drug procurement of public medical institutions, and saving medical expenses of 260 billion yuan Above, the burden on the masses is effectively alleviated.

On the morning of July 12, about 300 pharmaceutical companies participated in the bidding. This procurement was included in 60 medicines, involving common diseases such as hypertension, diabetes, anti -infection, digestive tract disease Drugs for major diseases such as kidney cancer and bowel cancer.

The average price reduction of drugs is 48%. According to the agreed purchase volume, it is expected to save 18.5 billion yuan per year. Taking the first -line liver cancer -targeted Yaolunbutoni capsule as an example, each drop from an average of 108 yuan to an average of 18 yuan, and a healing cycle can save 8,100 yuan. For the first time in the field of lowering blood pressure, it was included in the slow -controlled release agent. The price of nifeding horizontal control was 58%reduced, and the price of Matolol's slow -release tablet was 53%. The burden on the medication of patients with hypertension was significantly reduced. Anti -virus drug Osdivir's per tablet decreased from 4.5 yuan to 1 yuan. In addition, Pfizer's Donalin, Japan's Anstelai Mikafen Pure, Emmiro of Spain, Emmoro, and Bryko Xinyi, Italy, 4 original research medicines In the election, the average price was reduced by 67%.

Two Chengdu companies 15 varieties on the list

Although the official has not officially announced the results, many listed companies have issued an announcement to disclose the bidding. Coren Pharmaceuticals took the lead in announced their good news. As one of the winners of the national set in the past few times, Coron Pharmaceuticals also lived up to expectations and planned to win 11 varieties.

The announcement shows that the 14 varieties of Coron Pharmaceutical's large infusion leader Coren Pharmaceuticals were shortlisted for this centralized procurement. In the end, 11 of the phosphoric acid octhelviweer capsules, o'Nigitzole tablets, and sodium in injection The product is planned to win the bid. Among them, azolic acid injection (100ml: 5mg) that can be used to treat osteoporosis (100ml: 5mg) is a key variety of Kellen Pharmaceutical. Last year and the previous year, 88.21 million yuan and 101 million yuan were achieved.

It is worth noting that many varieties of Pharmaceuticals will be launched for the first time. Specifically include phosphoric acid octhevevir capsules, Elotininini hydrochloride, Malanic acid analidininibethe and Palonojano hydrochloride injection. Among them, the first three were approved for production last year. It is worth mentioning that the product regulations are 1.5ml: Palonojin in Palono Schoishel in Palono Scholes (used to prevent acute nausea and vomiting caused by chemotherapy). The last bus.

In addition to Kelun Pharmaceutical, Chengdu Yuandong Biological also announced the results of the drug to win the bid. The announcement shows that the company's products of sodium sodium sodium sodium sodium injection, citrate caffeine injection, U.S. -gold hydrochloride sustained -release capsules, and pomolic acid picotol are planned for centralized procurement. The sales revenue of these four products reached 324 million yuan last year, accounting for more than 30%of the company's annual operating income. However, the company said that the four -selected products are expected to be implemented in the fourth quarter, so it will not have a significant impact on the company's operating performance in 2022.

Stimulated by the news, both Kelly Pharmaceutical and Yuandong Biological Secondary market rose, of which Yuandong Bio rose by more than 6%.

Jianjianqiang Chain "Chengdu" created innovative drugs

Innovative drugs are one of the key industries cultivated in Chengdu. On December 10 last year, Chengdu held the first meeting of the leading group of the strong chain of the industrial construction circle. At the meeting, it was officially proposed that Chengdu will vigorously implement a strong chain of industrial construction, focusing on creating 20 industrial chains including innovative drugs.

Under the strong chain of the construction circle, the pace of R & D and innovative drugs in Chengdu enterprises has accelerated. Coron Pharmaceutical is one of the head suppliers of Guotai. It has won 11 varieties in the fifth batch of National Cai to win the bid and has become the largest number of bids. In the past few rounds of national mining, Colom Pharmaceutical has won a total of 25 products. This is due to the continuous volume of generic drugs approved by the company in recent years. Since the transformation in 2012, Colom Pharmaceutical has launched more than 300 drug research for domestic and foreign markets. In the five years from 2017 to 2021, the company was approved to list 94 products. Among them, in 2021, a direct harvest: 33 items were approved, and 30 other products were applied for production.

Last Friday, Chengdu held a symposium on a strong chain enterprise in the innovation medicine industry. Focusing on the strong chain of the industry, every problem raised by the enterprise, the relevant government functional departments responded.Chengdu is creating a better innovation ecology for the development of innovative drug companies, accelerating the development of the research and development of innovative drugs, and promoting Jianqiang Innovation Pharmaceutical Industry Chain.The reporter learned from the Chengdu Economic and Information Bureau that at present, Chengdu has formed an innovative pharmaceutical industry spatial layout of Chengdu Tianfu International Biological City, Chengdu Medical City, Tianfu Traditional Chinese Medicine City, West China Medical Meimei Health City, and Future Medical City.A number of chain -owned enterprises and leading enterprises such as Kellen Pharmaceutical, Better Pharmaceutical, Kanghong Pharmaceutical and other leading companies are accelerating the construction of an innovative drug industry with international competitiveness and regional driving force.Chengdu Daily Jinguan News Reporter Liu Taishan Editor He Qixie Editor Liu Yonghao

- END -